Antitumor activity of erythromycin on human neuroblastoma cell line (SH-SY5Y)

Abstract

Antitumor effects of erythromycin and the related mechanism were investigated in the present study. Neuroblastoma cells (SH-SY5Y) were exposed to erythromycin at different concentrations for different durations. Cell proliferation was measured by cell counting, and cell viability was examined by MTT assay. Cell cycle phase distribution and the cytosolic calcium level were detected by flow cytometry. Mitochondrial membrane potential was measured by the JC-1 probe staining and fluorescent microscopy. The expression of an oncogene (c-Myc) and a tumor suppressor [p21 (WAF1/Cip1)] proteins was analyzed by using Western blotting. Erythromycin could inhibit the proliferation of SH-SY5Y cells in a concentration- and time-dependent manner. The cell cycle was arrested at S phase. Mitochondrial membrane potential collapsed and the cytosolic calcium was overloaded in SH-SY5Y cells when treated with erythromycin. The expression of c-Myc protein was down-regulated, while that of p21 (WAF1/Cip1) protein was up-regulated. It was concluded that erythromycin could restrain the proliferation of SH-SY5Y cells. The antitumor mechanism of erythromycin might involve regulating the expression of c-Myc and p21 (WAF1/Cip1) proteins.

Keywords

erythromycin / c-Myc / p21 (WAF1/Cip1) / neuroblastoma

References

[1] NeuH.C.. The development of macrolides: clarithromycin in perspective. J Antimicrob Chemother, 1991, 27(SupplA): 1-9

[2] ReichC.. Erythromycin as an aid in the management of aleukemic myeloblastic leukemias. N Y State J Med, 1954, 54(15): 2208-2209

[3] HofsliE., Nissen-MeyerJ.. Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multidrug-resistant cells. Int J Cancer, 1989, 44(1): 149-154

[4] HamadaK., KitaE., SawakiM., et al.. Antitumor effect of erythromycin in mice. Chemotherapy, 1995, 41(1): 59-69

[5] VolbergW.A., KociB.J., SuW., et al.. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther, 2002, 302(1): 320-327

[6] ParkJ. R., EggertA., CaronH.. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am, 2010, 24(1): 65-86

[7] HahnW.C., WeinbergR.A.. Modeling the molecular circuitry of cancer. Nat Rev Cancer, 2002, 2(5): 331-341

[8] GorlovI.P., ByunJ., GorlovaO.Y., et al.. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics, 2009, 2: 48

[9] GearhartJ., PashosE.E., PrasadM.K.. Pluripotency redux—Advances in stem-cell research. N Engl J Med, 2007, 357(15): 1469-1472

[10] GustafsonW.C., WeissW.A.. Myc proteins as therapeutic targets. Oncogene, 2010, 29(9): 1249-1259

[11] PoluhaW., PoluhaD.K., ChangB., et al.. The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. Mol Cell Biol, 1996, 16(4): 1335-1341

[12] MckenzieP.P., DanksM.K., KriwackiR.W., et al.. P21Waf1/Cip1 dysfunction in neuroblastoma: a novel mechanism of attenuating G0–G1 cell cycle arrest. Cancer Res, 2003, 63(13): 3840-3844

[13] SeoaneJ., LeH.V., MassagueJ.. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature, 2002, 419(6908): 729-734

[14] June CH, Moore JS. Measurement of intracellular ions by flow cytometry. Curr Protoc Immunol, 2004, Chapter 5:Unit 5.5

[15] HuY., XiaX.Y., PanL.J., et al.. Evaluation of sperm mitochondrial membrane potential in varicocele patients using JC-1 fluorescent staining. Zhonghua Nan Ke Xue (Chinese), 2009, 15(9): 792-795

[16] LovmarM., NilssonK., VimbergV., et al.. The molecular mechanism of peptide-mediated erythromycin resistance. J Biol Chem, 2006, 281(10): 6742-6750

[17] ChenS.Z., JiangM., ZhenY.S.. HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin. Cancer Chemother Pharmacol, 2005, 56(2): 212-220

[18] BaumannS., FasS.C., GiaisiM., et al.. Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCgamma1- and Ca²⁺-dependent apoptosis. Blood, 2008, 111(4): 2354-2363

[19] DickJ.E.. Stem cell concepts renew cancer research. Blood, 2008, 112(13): 4793-4807

[20] DangC.V.. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol, 1999, 19(1): 1-11

[21] PelengarisS., KhanM., EvanG.. c-MYC: more than just a matter of life and death. Nat Rev Cancer, 2002, 2(10): 764-776

[22] LiF., WangY., ZellerK.I., et al.. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol, 2005, 25(14): 6225-6234

[23] GaoP., TchernyshyovI., ChangT.C., et al.. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature, 2009, 458(7239): 762-765

[24] DangC.V., LeA., GaoP.. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res, 2009, 15(21): 6479-6483

[25] Dominguez-SolaD., YingC.Y., GrandoriC., et al.. Non-transcriptional control of DNA replication by c-Myc. Nature, 2007, 448(7152): 445-451

[26] DaiM.S., JinY., GallegosJ.R., et al.. Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc. Neoplasia, 2006, 8(8): 630-644